TherapeuticsMD Statistics
Total Valuation
TherapeuticsMD has a market cap or net worth of $19.14 million. The enterprise value is $21.12 million.
| Market Cap | 19.14M |
| Enterprise Value | 21.12M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TherapeuticsMD has 11.53 million shares outstanding. The number of shares has increased by 18.23% in one year.
| Shares Outstanding | 11.53M |
| Shares Change (YoY) | +18.23% |
| Shares Change (QoQ) | +4.45% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 44.51% |
| Float | 9.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.29 |
| PS Ratio | 15.97 |
| Forward PS | n/a |
| PB Ratio | 0.67 |
| P/FCF Ratio | n/a |
| PEG Ratio | -0.73 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.78 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 150.04 |
Financial Efficiency
Return on equity (ROE) is -25.30% and return on invested capital (ROIC) is -20.00%.
| Return on Equity (ROE) | -25.30% |
| Return on Assets (ROA) | -15.60% |
| Return on Capital (ROIC) | -20.00% |
| Revenue Per Employee | $1.20M |
| Profits Per Employee | -$7.41M |
| Employee Count | 1 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -43,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.29% in the last 52 weeks. The beta is 1.03, so TherapeuticsMD's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -60.29% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 2.29 |
| Relative Strength Index (RSI) | 32.65 |
| Average Volume (20 Days) | 20,164 |
Short Selling Information
The latest short interest is 33,643, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 33,643 |
| Short Previous Month | 36,424 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.34% |
| Short Ratio (days to cover) | 2.75 |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of $1.20 million and -$7.41 million in losses. Loss per share was -$0.68.
| Revenue | 1.20M |
| Gross Profit | 1.20M |
| Operating Income | -7.00M |
| Pretax Income | -7.45M |
| Net Income | -7.41M |
| EBITDA | -6.47M |
| EBIT | -7.50M |
| Loss Per Share | -$0.68 |
Balance Sheet
The company has $4.34 million in cash and $6.32 million in debt, giving a net cash position of -$1.98 million or -$0.17 per share.
| Cash & Cash Equivalents | 4.34M |
| Total Debt | 6.32M |
| Net Cash | -1.98M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 28.66M |
| Book Value Per Share | 2.49 |
| Working Capital | 5.06M |
Cash Flow
| Operating Cash Flow | -14.73M |
| Capital Expenditures | n/a |
| Free Cash Flow | -14.73M |
| FCF Per Share | -$1.28 |
Margins
Gross margin is 100.00%, with operating and profit margins of -583.65% and -617.93%.
| Gross Margin | 100.00% |
| Operating Margin | -583.65% |
| Pretax Margin | -621.52% |
| Profit Margin | -617.93% |
| EBITDA Margin | -539.95% |
| EBIT Margin | -625.69% |
| FCF Margin | -1,228.19% |
Dividends & Yields
TherapeuticsMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.23% |
| Shareholder Yield | -18.23% |
| Earnings Yield | -38.70% |
| FCF Yield | -76.92% |
Analyst Forecast
The average price target for TherapeuticsMD is $5.00, which is 201.21% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.00 |
| Price Target Difference | 201.21% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
TherapeuticsMD has an Altman Z-Score of -31.17 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -31.17 |
| Piotroski F-Score | 3 |